The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November Scorecard Number of Signals 8 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 5 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 19 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 13 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 49 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 11% Other stats: Number of signals over $10/share 30 Number […]
On October 2, Paratek Pharmaceuticals, Inc. (PRTK) announced that the company received FDA approval of NUZYRA™ (omadacycline) to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA is an antibiotic that can be administered either orally or through a once-daily IV treatment. Paratek plans to have the drug available in […]
On October 1, Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE) reported results from their phase 3 clinical trial of ECELON-2. The trial demonstrated a statistically significant improvement in progression-free survival for patients using their drug Adcentris in combination with chemotherapy when compared to chemotherapy alone. It is the first randomized Phase 3 […]
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]
On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]
On September 5, ProQR Therapeutics, N.V. (PRQR) announced positive results from its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA 10) due to a mutation in the CEP290 gene. LCA10 usually leads to childhood blindness and currently has no available treatment options. Patients in the trial had rapid and sustained […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 39 Percent Correct – Prev Close to 5-day Peak 97% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 25 Number […]
INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids […]
Simply register below to get sample signals as they come out!
